Table 2.
Comparison of Treatment and Response Outcomes for Patients With and Without Esophageal Candidiasis
| Treament characteristic | No candidiasis (n = 466) | Candidiasis (n = 34) | Pa |
|---|---|---|---|
| Type of steroid used (n, %) | .05 | ||
| Fluticasone | 140 (30) | 17 (50) | |
| Budesonide | 325 (70) | 17 (50) | |
| Ciclesonide | 1 (< 1) | 0 (0) | |
| Mean steroid dose (mcg ± SD) | 1688 ± 724 | 1849 ± 505 | .20 |
| Symptom response (n, %)b | 122 (75) | 20 (87) | .22 |
| Post-treatment peak eosinophil count (mean eos/hpf ± SD) | 26.2 ± 38.1 | 8.8 ± 20.0 | .009 |
| P value vs baseline | <.001 | <.001 | |
| Histologic response (n, %) | |||
| < 15 eos/hpf | 252 (54) | 29 (85) | <.001 |
| ≤ 6 eos/hpf | 222 (48) | 25 (74) | .004 |
| < 1 eos/hpf | 133 (29) | 14 (41) | .12 |
| Post-treatment endoscopic findings (n, %) | |||
| Exudates | 113 (24) | 11 (32) | .30 |
| Rings | 205 (44) | 15 (44) | .99 |
| Edema | 138 (30) | 7 (21) | .26 |
| Furrows | 220 (47) | 9 (26) | .02 |
| Stricture | 141 (30) | 14 (41) | .18 |
| Narrowing | 77 (17) | 5 (15) | .78 |
| Crepe-paper mucosa | 4 (1) | 0 (0) | .59 |
| Dilation | 139 (30) | 13 (38) | .30 |
| Endoscopic response (n, %) | 324 (70) | 31 (91) | .008 |
| Post-treatment endoscopic severity (mean scores ± SD) | |||
| EREFSc | 2.3 ± 1.9 | 1.7 ± 1.4 | .14 |
| P value vs baseline | <.001 | <.001 | |
| ESSc | 1.76 ± 1.5 | 1.65 ± 1.4 | .67 |
| P value vs baseline | <.001 | <.001 |
a
Means between compared with 2-sample t-test; means among groups compared with a paired t-test; proportions compared with chi-squared.
b
Available for 162 without candidiasis and 23 with candidiasis; EREFS, EoE endoscopic reference score.
c
Available for 261 without candidiasis and 24 with candidiasis; ESS, Endoscopic Severity Score, for which all data available.